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ABSTRACT 
The focal adhesion tyrosine kinase (PTK2) is often over-expressed in human hepatocellular 
carcinoma (HCC) and several reports have linked PTK2 depletion and/or pharmacological 
inhibition to reduced tumorigenicity. However, the clinical relevance of targeting PTK2 still 
remains to be proven. Here we present two highly selective and functional PTK2 PROTACs 
utilizing VHL and cereblon ligands to hijack E3 ligases for PTK2 degradation. BI-3663 
(cereblon-based) degrades PTK2 with a median DC50 of 30 nM to > 80 % across a panel of 
eleven HCC cell lines. Despite effective PTK2 degradation, these compounds did not phenocopy 
the reported anti-proliferative effects of PTK2 depletion in any of the cell lines tested. By 
disclosing these compounds, we hope to provide valuable tools for the study of PTK2 
degradation across different biological systems.
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Introduction
Focal adhesion tyrosine kinase (PTK2) is a cytoplasmic protein tyrosine kinase that is 
overexpressed and activated in many types of advanced-stage solid cancers. PTK2 is reported to 
play an important role in adhesion, spreading, motility, invasion, metastasis, survival, 
angiogenesis, epithelial to mesenchymal transition (EMT), cancer stem cells and the tumour 
microenvironment1,2. Overexpression and activation of PTK2 is associated with several human 
malignant diseases, including colorectal3, ovarian4, esophageal5 and hepatocellular carcinoma 
(HCC)6 and is correlated with poor overall patient survival7, 8. Hepatocellular carcinoma (HCC) 
is the most common type of liver cancer in humans, accounting for 70–85 % of primary liver 
malignancies, and is the third leading cause of cancer-related death worldwide9, 10. HCC is 
associated with an extremely poor prognosis since it is often diagnosed at advanced stages, 
restricting the currently available therapeutic options to either surgical resection or liver 
transplantation11, 12. Several reports link PTK2 depletion or pharmacological inhibition of its 
kinase activity to reduction of in vitro and in vivo tumorigenicity in HCC models13, 14. However, 
the disconnect between modulation of intracellular PTK2 autophosphorylation and growth 
inhibition as well as the often suboptimal selectivity profile of the inhibitors used makes it 
difficult to link the reported blockade of HCC tumour initiation and maintenance to PTK2 
inhibition. 
We previously described BI-853520, a novel ATP-competitive inhibitor distinguished by high 
potency and selectivity15, 16. BI-853520 inhibits PTK2 autophosphorylation in cancer cell lines 
and blocks anchorage-independent proliferation with single digit nmol/L potency. In contrast, 
cells grown in conventional surface (2-D) culture were found to be 1,000-fold less sensitive to 
BI-853520. These findings are in keeping with the described role of PTK2 in integrin mediated 
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signaling2, 17. We reasoned that ligands derived from BI-853520 would be suitable to develop 
PROTACs (PROteolysis TArgeting Chimeras) and compare the potential anti-oncogenic effects 
of PTK2 depletion as compared to inhibition of its kinase activity18. 
PROTACs are bifunctional degrader molecules composed of a ligand for the target protein 
linked to a module that recruits an E3 ligase19, 20. PROTACs represent an emerging therapeutic 
strategy to use small molecules to deplete a protein by repurposing the ubiquitin-proteasome 
system21, 22. Upon formation of a ternary complex target:PROTAC:E3 ligase23-25, the protein of 
interest is ubiquitinated and subsequently degraded by the proteasome. Compared to 
pharmacological inhibition of the kinase function, protein degradation more closely resembles 
genetic approaches to interfere with PTK2 expression in HCC models. Moreover, PROTAC 
molecules can add a layer of target selectivity beyond that expected from the constitutive binding 
ligands, thus providing highly selective degraders with potentially reduced off-target effects25-28. 
The most common E3 ligases currently recruited using PROTACs are the von Hippel-Lindau 
(VHL) protein complex CRL2VHL and the cereblon (CRBN) complex CRL4CRBN. PROTACs 
consisting of the same target ligand but employing either VHL or CRBN ligands can exhibit 
different degradation selectivity and efficacy26, 29-31. Emerging evidence suggests that it might be 
beneficial to develop parallel chemical series hijacking different E3 ligases. First, expression of 
the recruited E3 ligase and intrinsic activity may be context-dependent and vary widely amongst 
cell- and tissue types32. Second, resistance mechanisms could potentially arise from loss of the 
recruited E3 ligase, as demonstrated by the correlation between level of CRBN and response to 
CRBN-recruiting drugs in multiple myeloma33. Flexible choice of the recruited E3 ligase may 
therefore aid targeted protein degradation. 
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Recently, the first PTK2 PROTACs have been reported. Conjugating the known pyrimidine-
based ALK inhibitors, TAE684 and LDK378, to the cereblon ligand pomalidomide led to the 
discovery of the first small molecule degraders of ALK that concomitantly degrade, PTK2, 
Aurora A, FER, and RPS6KA134. A PROTAC based on a highly promiscuous kinase inhibitor 
was also reported to degrade PTK2 amongst 27 additional kinases35. While both studies 
demonstrate that PTK2 can be targeted by a PROTAC approach, they also clearly highlight the 
need for more selective PTK2 PROTACs to address its role in cancer. Motivated by the potential 
of targeting kinase-independent functions of PTK2 with a low molecular weight modality, we 
initiated a PROTAC medicinal chemistry campaign to artificially recruit PTK2 to two different 
E3 ligases. 
Here, we show the synthesis and characterization of the first probe-quality PROTACs targeting 
PTK2. Structure-guided conjugation of a highly selective PTK2 inhibitor to either a CRBN or 
VHL ligand led to selective PTK2 degraders. We profiled both PROTACs for degradation 
efficacy and anti-proliferative activity in a panel of HCC, tongue squamous cell carcinoma, 
melanoma, pancreatic ductal adenocarcinoma and non-small cell lung cancer cell lines several of 
which were recently shown to depend on expression of PTK2 by functional RNA interference 
screening36. Despite potent and complete degradation of PTK2, both degraders failed to show the 
anticipated growth reduction beyond the effect of a PTK2 kinase inhibitor in these models. 
Results and Discussion
We designed a set of PTK2 PROTACs recruiting the two E3 ubiquitin ligases, VHL and 
CRBN, to test whether PTK2 can be targeted by targeted proteolysis. Making use of available E3 
ligase ligands, we aimed at maximizing the chance of developing an active PTK2 degrader tool 
compound. We selected the highly selective ATP competitive inhibitor BI-4464 (1, Scheme 1), a 
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close analogue of the 2-aminophenyl-4-phenoxypyrimidine BI-85352015 currently being tested in 
clinical trials as a PTK2 ligand. The choice of BI-4464 as a target ligand was driven by its high 
binding affinity and exquisite selectivity across a large kinase panel (see also Figure 3). We 
believe that this exceptional selectivity originates from a unique binding mode which seems to be 
less tolerated by other kinases. To design a first generation of degraders, we inspected the crystal 
structure of BI-4464 bound to the PTK2 kinase domain to identify suitable attachment points and 
vectors for linker conjugation (Figure 1). The structure shows binding of the trifluoro-
aminopyrimidine moiety to the backbone nitrogen and carbonyl of cysteine 502 in the hinge 
region via two hydrogen bonds. In addition, the oxygen of the dihydroindenone moiety forms 
another hydrogen bond to the backbone nitrogen of aspartic acid 564. The N-methyl piperidine 
group of BI-4464 was identified as solvent-exposed and not involved in any interactions with the 
protein. We further selected 237 and pomalidomide 3,38 (Scheme 1) as VHL and CRBN ligands, 
respectively. Their terminal amino groups (Table 1 and Scheme 1) were conjugated via an amide 
bond to the linker consisting of up to five PEG units without perturbing the interaction with the 
E3 ligases, as previously demonstrated28, 31, 39, 40. 
Scheme 1. Chemical structures of BI-4464 ligand 1, VHL ligand 237, 41, 42 and CRBN ligand 338.
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Figure 1. Structure of BI-4464 bound to PTK2 (PDB ID 6I8Z). Hydrogen bonds to cysteine 502 
and aspartic acid 564 are depicted in blue.
To obtain the described compounds 6 and 8 (Table 1), a convergent synthesis was developed to 
connect 1a to each E3 ligase ligand 2 and 3. PEG linkers 1-5 (Scheme 2 shows an example of 
linker length three) were synthesized and profiled. The synthesis of ligand 1a was carried out as 
outlined in Scheme 2. Aromatic nucleophilic substitution of the 4-chloropyrimidine 4 with 
7‐hydroxy‐2,3‐dihydroindan‐1‐one produced the carboxylic acid 1a. Amide coupling of azido-
PEG-3-propanoic acid and azido-PEG-3-acetic acid to the E3 ligase ligand 2 and 3 followed by 
catalytic hydrogenation produced the amines 5b, 7b and 10b in good yields. The final PROTACs 
6, 8 and the cis-VHL analogue 11 were synthesized following amide coupling of the ligase linker 
conjugates 5b, 7b and 10b with 1a.
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Table 1. Binary affinities of compounds 1, 6, 8 for PTK2 and the respective PTK2 degradation 
data in A549 cells. 
A549 cells, 18h**
Code N X
E3 
ligase 
ligand
PTK2*  
pIC50 pDC50 Dmax [%]
1 (BI-4464) - - - 7.8 ± 0.1 >10,000 -
6 (BI-3663) 3 CONH POMA 7.7 ± 0.1 7.6 ± 0.1 95 ± 4
8 (BI-0319) 2
O-CH2-
CONH
2 7.7 ± 0.1 6.7 ± 0.4 80 ± 9 
* Thermo Fisher selectScreen Kinase Profiling Services, Z´-Light, ATP@Km, pIC50 
± STDEV ** Degradation activity is reported as concentration needed to achieve 50 % 
PTK2 protein degradation (pDC50 ± STDEV) and maximal achievable protein 
degradation (Dmax) relative to DMSO. PTK2 levels were determined by protein 
capillary electrophoresis and normalized to GAPDH. (N = 3)
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Scheme 2. Synthesis of the PTK2 degraders.a
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5a, R = N3
5b, R = NH2 6 (BI-3663)
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a
c,d e
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i,j k
1a
1a
1a
8 (BI-0319)
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10a, R = N3
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aReaction Conditions: (a) Cs2CO3, MgSO4, dioxane, 80°C, 16 h, 78%; (b) HATU, DIPEA, DMF, rt, 2 h, 75%; (c) 
T3P, pyridine, DMF, 80°C, 3h, 76%; (d) H2 (6 bar), Pd/C (10%), MeOH, rt, 3 h, 90%; (e) 1a, HATU, DIPEA, DMF, 
rt, 18 h, 10%; (f) HATU, DIPEA, DMF, rt, 1 h, 63%; (g) H2 (5 bar), Pd/C (10%), MeOH, rt, 2.5 h, 82%; (h) 1a, 
HATU, DIPEA, DMF, rt, 24 h, 34%; (i) HATU, DIPEA, DMF, rt, 2 h, 47%; (j) H2 (6 bar), Pd/C (10%), MeOH, rt, 3 
h, 98%; (k) 1a, HATU, DIPEA, DMF, rt, 16 h, 69%.
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We next tested PTK2 degradation by all synthesized PROTACs (sampling linker lengths of up 
to five ethylene glycol units) after 16 hours treatment of the human lung adenocarcinoma cell 
line A549. PROTACs 6 (BI-3663) and 8 (BI-0319) were identified as the best degraders in the 
CRBN and VHL series and characterized in greater detail. The CRBN-based PROTAC 6 (BI-
3663) degraded PTK2 potently (DC50 = 27 nM) with a maximally obtainable degradation at the 
chosen experimental conditions of 95% (Dmax) while the best VHL-based PROTAC 8 (BI-0319) 
only achieved partial degradation (Dmax = 80 %) and was less potent (DC50 = 243 nM) in A549 
cells (Table 1 and Figure 2). Further, both PROTACs show a small apparent hook effect in A549 
cells at 25 µM. Consistent with VHL dependency, which requires the substituents of the 
pyrrolidine in the VHL ligand in a trans configuration28, degradation of PTK2 by 8 (BI-0319) 
was abolished by switching the stereochemistry of the pyrrolidine substituents to the cis 
configuration (11, BI-4206) (Figure 2A). Moreover, as predicted for neddylation-dependent E3 
ligases such as VHL and CRBN, the NEDD8 inhibitor MLN492443 (MLN) inhibited degradation 
of PTK2 by 6 (BI-3663) and 8 (BI-0319) (Figure 2A and B). Importantly, the PTK2 ligand 1 
itself did not affect PTK2 levels. 
We assessed PTK2 target engagement in vitro to understand the effect of the linker and exit 
vector on PTK2 inhibition of PROTACs 6 and 8. As predicted from the structure-based design, 
both PROTACs and the PTK2 ligand inhibited PTK2 in vitro with virtually identical potencies 
(IC50 = 18 and 19 versus 17 nM for the PTK2 inhibitor 1). 
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Figure 2. Characterization of BI-0319 and BI-3663 in A549 cells. A) A549 cells were treated 
with the indicated concentrations of BI-0319 in presence or absence of the NEDD8 inhibitor 
MLN4924 (MLN, 3 µM) or an inactive stereoisomer (BI-4206) for 18 h. PTK2 levels were 
determined by protein capillary electrophoresis and normalized to GAPDH. Values are stated as 
percentages of DMSO controls (POC). B) A549 cells were treated with the indicated 
concentrations of BI-3663 in presence or absence of the NEDD8 inhibitor MLN4924 (3 µM) or 
with the PTK2 inhibitor BI-4664 for 18 h. PTK2 levels were measured and are stated as in A. 
In contrast to the previously published less selective PTK2 degraders34, 35, we believe that a 
defining aspect of the PTK2 degraders described here is their high selectivity, which should 
enable validation of the relevance of PTK2 scaffolding functions in biologically relevant 
contexts. Indeed, of the 397 kinases tested in a kinase panel screening only 2 were inhibited by 
more than 90 % at 1 µM (Figure 3). Interestingly, BI-0319 (8) is more selective than the already 
highly selective PTK2 TKI 1 (BI-4464). We assume that the kinase selectivity panel for BI-3663 
(6) might be comparable to BI-0319 since both exit vector and linker are identical for a distance 
of nine atoms from the piperidine moiety of the PTK2 ligand
Page 12 of 52
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Popow et al. 13
Figure 3. Kinase selectivity panels of the PTK2 ligand BI-4464 and VHL PROTAC BI-0319. 
Bars indicate percent inhibition at 1 µM of either compound.
We employed multiplexed isobaric tagging mass spectrometry to assess the cellular selectivity 
of BI-3663 (6) and BI-0319 (8) for PTK2 degradation and identify potential degradation off-
targets in a quantitative and unbiased manner. Amongst the 6,008 proteins quantified in this 
analysis in A549 cells, PTK2 showed a distinct and significant change in abundance upon 
treatment with either PROTAC. (Figure 4 and Supplemental table 3). Neither BI-3663 (6) nor 
BI-0319 (8) induced any significant changes in abundance of other detectable kinases, thus 
confirming the high selectivity of both degraders within the kinase family. Of note, the two most 
prominent kinase off-targets of the inhibitor were not detected in this dataset. Interestingly BI-
0319 (8) – but not BI-3663 (6) – also induced a significant change of PDE6D levels (Figure 4A), 
a finding corroborated by immunoblot in A549 cells (Supplemental figure 1).
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Figure 4. Total proteome analysis of A549 cells treated with 3 µM of BI-0319 (A) or BI-3663 
(B) for 18 h and compared to DMSO controls. Samples were run in biological triplicates and 
analyzed by mass spectrometry. Volcano plot displays log2 of fold-change in abundance versus –
log10 of adjusted p value (N = 3).
Having established the high selectivity of both PROTACs, in particular of the CRBN-based 
BI-3663, we tested their potential to degrade PTK2 in a panel of eleven HCC cell lines (Table 3 
and Supplemental figure 2 and 3). Both PROTACs show comparable degradation potencies and 
efficacies in the 11 HCC cell lines tested (BI-3663 mean pDC50 = 7.45±0.60 versus BI-0319 
mean pDC50 = 7.08±0.52). Whereas PTK2 levels in cell lines such as SNU-398 were equally 
sensitive to treatment with both PROTACs, other cell lines, such as Hep3B2.1-7 exhibited a >10 
fold difference of the potencies of 6 and 8 in cell-based PTK2 degradation assays, as observed 
for A549 cells during the profiling experiments (Figure 5 and Table 2). 
It is not unexpected that heterobifunctional molecules unavoidably result in high molecular 
weight compounds, making it difficult to balance their physicochemical properties in a manner 
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Popow et al. 15
consistent with acceptable permeability and solubility. While both PROTACs have a comparable 
low aqueous solubility and high tPSA (241,243 Å2), PROTAC 6 has one hydrogen bond donor 
(HBD) more than PROTAC 8.   The negative impact on permeability for 6 might be 
compensated by the higher lipophilicity (ClogP 6.9 vs 3.8) however, the higher lipophilicity  of 6 
also translates in higher PPB and lower free fraction (6: 4.0%, 8: 11.3; Supplemental table 1). 
As assessed by the Caco2 assay, both PROTACs exhibit low permeability and significant 
efflux (Supplemental table 1). Therefore, high efflux might compromise cellular exposures 
achieved by both PROTACs. We reasoned that blocking multidrug efflux pumps (such as the 
Multidrug-Resistance-Protein 1, PGP) might boost the potency and efficacy of both PROTACs 
in cell lines with a large discrepancy between biochemical and intracellular activity. 
Cyclosporine A (CsnA) has been described as a substrate of several drug transporters including 
PGP44 and can therefore be used to saturate these transporters at high concentrations. 
Consequently, we assessed PTK2 degradation by both PROTACs upon addition of CsnA to 
saturate drug transport in Hep3B2.1-7 (Figure 6A and B). Indeed, we observed a comparable 
shift in the potency of PTK2 degradation for both PROTACs (Table 2), consistent with efflux 
contributing to their reduced degradation efficacy in this cell line. Of note, CsnA only had a 
minor effect on PTK2 levels (Figure 6C).
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Figure 5. Cumulative analysis of half-maximal effective concentrations (DC50, A) and maximal 
degree of PTK2 degradation (Dmax, B) achieved by BI-0319 or BI-3663. pDC50 and Dmax at 18 
h were determined as indicated in supplemental figures 2 and 3.
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Figure 6. Analysis of PTK2 degradation in Hep3B2.1-7 cells. A) cells were treated with the 
indicated concentrations of BI-0319 for 18 h in presence (red triangles) or absence (blue circles) 
of 10 µM cyclosporine A (CsnA). B) cells were treated for 18 h with the indicated concentrations 
of BI-3663 in presence (red triangles) or absence (green circles) of 10 µM CsnA. C) cells were 
treated with 10 µM CsnA for 18 h. D) Time course analysis of PTK2 levels in cells treated with 
3 µM BI-0319. E) Time course analysis of PTK2 levels in cells treated with 3 µM BI-3663. 
Values state PTK2 protein levels normalized to GAPDH relative to DMSO (or CsnA only) 
controls.
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Table 2. PTK2 degradation data of BI-3663 and BI-0319 in A549 and Hep3B2.1-7 cells. 
A549, 18 h* Hep3B2.1-7, 18 h * Hep3B2.1-7, 18 h *
+ 10 µM CsnA
pDC50 Dmax 
[%]
pDC50 Dmax [%] pDC50 Dmax [%]
6 (BI- 3663) 7.6 ± 0.1 95 ± 4 7.9 96 9.0 94
8 (BI -0319) 6.7 ± 0.4 80 ± 9 6.2 59 7.4 88
* Degradation activity is reported as concentration needed to achieve 50 % PTK2 protein 
degradation (pDC50 ± STDEV ) and maximal achievable protein degradation (Dmax) relative to 
DMSO. 
PROTACs 6 and 8 differ considerably with respect to their cellular degradation rate in 
Hep3B2.1-7 cells. The CRBN-based PROTAC 6 achieved complete degradation of PTK2 after 
five hours whereas the VHL-based PROTAC 8 achieved maximal degradation only after 20 
hours (Figure 6D and E). Of note, the CRBN-based PROTAC 6 was considerably less stable in 
cell assay buffer containing 10% FCS (M+18 and +32 observed) than the VHL-based PROTAC 
8 (Supplemental Table 1). PROTAC 6 was found to be stable as a solid and in DMSO stock 
solution (>3 month, data not shown). Despite this previously reported instability of CRBN based 
PROTACs45 PROATC 6 as well as PROTAC 8 showed comparable maximal degradation of 
PTK2 after 18 h and 72h days incubation (Supplemental figure 6). Taken together, this indicates 
that the both PROTACs 6 and 8 are suitable probes to further study the role of PTK2  in a broad 
range of tumour cell lines. 
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Reasoning that additional targeting of the scaffolding functions of PTK2 by PROTAC-
mediated degradation might result in enhanced efficacy as compared to inhibition of its kinase 
activity, we next tested the effect of PROTAC-mediated PTK2 degradation on proliferation of 
the same HCC cell lines. Surprisingly, efficient depletion of PTK2 by both PROTACs (Table 3 
and Supplemental figures 2 and 3) did not affect proliferation of the tested cell lines more 
severely than the PTK2 inhibitor BI-4464 in standard culture conditions or in anchorage-
independent growth assays (Table 3, Supplemental figures 4 and 5). Notably, sensitivity to 
genetic depletion of PTK2 has been described for several of the tested cell lines (Supplemental 
table 4). One explanation may be that effects on proliferation may require long-term depletion of 
PTK2. To further address this, we treated cell lines with reported high sensitivity to genetic 
depletion of PTK236, 46 (Supplemental table 4) for 21 days with either PROTAC 6 (BI-3663) or 8 
(BI-0319) or the PTK2 inhibitor 1 (BI-4464). Despite the effective depletion of PTK2 even after 
21 days, we did not observe any pronounced anti-proliferative effects for any of the tested cell 
lines (Supplemental figure 6). Notably, CRISPR-based genetic validation in cultured HuH-1 
cells also resulted in a weak dependency on PTK2 (Supplemental figure 7). Taken together, these 
data questions the scaffolding function of PTK2 being required for in vitro proliferation of the 
tested cell lines beyond the effect of inhibition of its kinase activity. Nevertheless, our 
observations indicate that both probes can be used to effectively reduce PTK2 protein levels in 
long term experiments in cultured cells. 
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Table 3. Degradation characteristics and effect on proliferation of BI-3663 (6) and BI-0319 (8) 
in HCC lines. 
BI-3663 BI-0319 BI-4464
Cell line
pDC50
Dmax, 
[%]
pIC50 
(proliferation)
pDC50
Dmax, 
[%]
pIC50 
(proliferation)
pIC50 
(proliferation)
SNU-387 7.6 90.0 <4.6 7.5 98.0 5.3 5.2
HUH-1 6.6 50.0 4.6 7.1 79.0 4.7 5.4
Hep3B2.1-7 7.9 96.0 4.6 6.2 59.0 5.2 5.3
HepG2 7.5 89.0 <4.6 6.2 65.0 <4.6 5.5
SK-Hep-1 7.5 89.0 5.8 6.9 87.0 5.1 5.2
HLF 6.4 30.0 <4.6 7.4 66.0 <4.6 5.4
SNU-398 8.5 95.0 <4.6 8.0 99.0 5.1 5.2
HUCCT1 7.9 90.0 <4.6 6.9 86.0 5.2 5.2
HLE 6.8 79.0 <4.6 7.6 85.0 5.0 5.1
HuH-7 7.3 93.0 <4.6 7.0 79.0 5.4 5.4
SNU-423 7.9 93.0 4.7 7.1 87.0 5.2 5.4
Conclusion
We describe the development of two highly selective and functional PROTACs to degrade the 
PTK2 protein, a kinase of significant relevance to cancer research, in particular, in the area of 
hepatocellular carcinoma. Structure-guided conjugation of a highly selective PTK2 inhibitor BI-
4464 to either a CRBN or VHL ligand via polyethylene glycol linkers led to the selective PTK2 
degraders BI-0319 and BI-3663, respectively, using orthogonal E3 ligase binders. Both 
PROTACs were characterized with respect to in vitro PTK2 engagement, ligase dependence 
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selectivity (kinase inhibition as well as whole cell proteome) and degradation efficacy (DC50 and 
Dmax) in twelve cell lines (one lung cancer and eleven hepatocellular carcinoma cell lines). Both 
PROTACs are highly selective E3 ligase-dependent PTK2 degraders and show overall 
comparable potencies and efficacies of PTK2 degradation in the 12 cell tested lines. Whereas 
PTK2 levels in cell lines such as SNU-398 were equally sensitive to treatment with both 
PROTACs, other cell lines, such as Hep3B2.1-7 exhibited a more than ten-fold difference in 
cellular potency. This difference in degradation efficacy in Hep3B2.1-7 cells was associated with 
a higher degradation rate of BI-3663. Despite the efficient depletion of PTK2, treatment with 
either PROTAC did not affect proliferation of the tested cell lines in either short or long term 
assays in vitro (6 vs 21 days) beyond the effect achieved by a PTK2 kinase inhibitor. Taken 
together, these data suggest that PROTACs 6 (BI-3663) and 8 (BI-0319) mediated PTK2 
depletion is likely insufficient to affect proliferation in vitro under the conditions tested beyond 
the effect of inhibition of its kinase activity. Nevertheless, both probes provide valuable tools to 
effectively reduce PTK2 protein levels in experimental conditions that might be better suited to 
reveal and differentiate between kinase- dependent and -independent functions of PTK2. BI-
3663, BI-0319 and its inactive control BI-4206 will be made available to all scientists via our 
open innovation portal opnMe.
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EXPERIMENTAL SECTION
Chemistry. Synthesis. Unless otherwise indicated, all reactions were carried out in standard 
commercially available glassware using standard synthetic chemistry methods. Air-sensitive and 
moisture-sensitive reactions were performed under an atmosphere of dry nitrogen or argon with 
dried glassware. Commercial starting materials were used without further purification. Solvents 
used for reactions were of commercial “dry”- or “extra-dry” or “analytical” grade. All other 
solvents used were reagent grade.
The thin layer chromatography is carried out on ready-made silica gel 60 TLC plates on glass 
(with fluorescence indicator F-254) made by Merck. The preparative high pressure 
chromatography (RP-HPLC) is carried out on Gilson systems with columns made by Waters 
(names: Sunfire™ Prep C18, OBD™ 10 µm, 50x150 mm or XBridge™ Prep C18, OBD™ 10 
µm, 50x150 mm) and YMC (names: Actus-Triart Prep C18, 5 µm, 30x50 mm). Different 
gradients of MeCN/H2O are used to elute the compounds, for acidic conditions 0.1 % HCOOH is 
added to the water. For the chromatography under basic conditions the water is made alkaline as 
follows: 5 mL NH4HCO3 solution (158 g in 1 L H2O) and 2 mL NH3 (28 % in H2O) are 
replenished to 1 L with H2O.
All compounds had a purity >95% acording to HPLC and NMR analysis acquired with the 
systems and parameters stated in the following. HPLC samples were analyzed on an Agilent 
1200 series LC system coupled with an Agilent 6140 mass spectrometer. Purity was determined 
via UV detection with a bandwidth of 170nm in the range from 230-400nm. LC parameters were 
as follows: Waters Xbridge C18 column, 2.5µm particle size, 2.1 x 20mm. Total run time 3.1 
minutes, flow 1ml/min, column temperature 60°C and 5µl injections. Solvent A (20mM 
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NH4HCO3/ NH3  pH 9), solvent B (MS grade acetonitrile). Start 10% B,  gradient 10% - 95% B 
from 0.0 - 1.5min, 95% B from 1.5  - 2.0min, gradient 95% - 10% B from 2.0 – 2.1min. 
NMR experiments were recorded on a Bruker Avance HD 500 MHz spectrometer equipped 
with a TCI cryoprobe at 298 K. Samples were dissolved in 600 μL DMSO-d6 and TMS was 
added as an internal standard. 1D 1H spectra were acquired with 30° excitation pulses and an 
interpulse delay of 4.2 sec with 64k data points and 20 ppm sweep width. 1D 13C spectra were 
acquired with broadband composite pulse decoupling (WALTZ16) and an interpulse delay of 3.3 
sec with 64 k data points and a sweep width of 240 ppm. Processing and analysis of 1D spectra 
was performed with Bruker Topspin 3.2 software. No zero filling was performed and spectra 
were manually integrated after automatic baseline correction. Chemical shifts are reported in 
ppm on the δ scale.
HSQC spectra were recorded on all samples to aid the interpretation of the data and to identify 
signals hidden underneath solvent peaks. Spectra were acquired with sweep widths obtained by 
automatic sweep width detection from 1D reference spectra in the direct dimension with 1k 
datapoints and with 210 ppm, and 256 datapoints in the indirect dimension. 
For HRMS a LTQ Orbitrap XL (Thermo Scientific) coupled with a Triversa Nanomate 
Nanospray ion source (ADVION Bioscience Inc.) was used.
3-methoxy-4-({4-[(3-oxo-2,3-dihydro-1H-inden-4-yl)oxy]-5-(trifluoromethyl)pyrimidin-2-
yl}amino)benzoic acid (1a). 4-{[4-chloro-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-
methoxybenzoic acid (447, 1.00g, 1eq) and 7-hydroxy-2,3-dihydro-1H-inden-1-one (879 mg, 2 
eq) were taken up in dioxane (10 mL), then Cs2CO3 (4.686 g, 5 eq) was added. The reaction 
mixture was stirred at 80°C for 16 h. The reaction mixture was diluted with H2O and acetonitrile 
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and concentrated under reduced pressure. The residue was purified by preparative RP-HPLC 
under basic conditions using MeCN/H2O as eluents in a gradient from 20:80 to 65:35 over 12 
min. (column: XBridge™ Prep C18, OBD™ 10 µm, 50x150 mm; flow: 110 mL/min). Product 
containing fractions were freeze dried to give 3-methoxy-4-({4-[(3-oxo-2,3-dihydro-1H-inden-4-
yl)oxy]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzoic acid (1a, 1.03 g, 78% yield) as brown 
solid. 1H NMR (500 MHz, DMSO-d6) δ = 12.85 (br s, 1H), 8.86 (s, 1H), 8.74 (s, 1H), 7.80 (t, 
J=7.88 Hz, 1H), 7.60 (d, J=7.88 Hz, 1H), 7.41 (d, J=0.95 Hz, 1H), 7.32 (br d, J=1.00 Hz, 1H), 
7.24 (d, J=7.88 Hz, 1H), 7.15 (br d, J=1.00 Hz, 1H), 3.80 (s, 3H), 3.05-3.17 (m, 2H), two protons 
under DMSO. 13C NMR (125 MHz, DMSO-d6) δ = 203.4, 167.3, 166.4, 161.0, 158.4, 157.8, 
149.7, 148.0, 137.0, 131.7, 128.9, 126.5, 125.5, 121.8, 121.1, 123.9, 120.4, 111.7, 101.5, 56.3, 
36.7, 25.8. HRMS (m/z): [M+H]+ calculated for C22H16F3N3O5, 459.10421; found, 459.10411. 
HPLC-MS tR = 1.00 min. 
3-methoxy-N-(1-methylpiperidin-4-yl)-4-({4-[(3-oxo-2,3-dihydro-1H-inden-4-yl)oxy]-5-
(trifluoromethyl)pyrimidin-2-yl}amino)benzamide (1, BI-4464). In a glass vial, 3-methoxy-4-
({4-[(3-oxo-2,3-dihydro-1H-inden-4-yl)oxy]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzoic 
acid (1a, 100 mg, 1 eq) was dissolved in DMF (1 mL). DIPEA (86 µl, 3 eq) and HATU (114 mg, 
1.5 eq) were added. After the reaction mixture was stirred at rt for 5 min, 1-methylpiperidin-4-
amine (46 mg, 52 µl, 2 eq) was added. The mixture was stirred at rt for 2 h. The reaction mixture 
was diluted with MeCN and H2O and filtered through a syringe filter prior to purification via RP-
HPLC under basic conditions using MeCN/H2O as eluents in a gradient from 30:70 to 98:2 over 
8 min (column: YMC Actus-Triart Prep C18, 5 µm, 30x50 mm; flow: 50 mL/min). Product 
containing fractions were freeze dried to give 3-methoxy-N-(1-methylpiperidin-4-yl)-4-({4-[(3-
oxo-2,3-dihydro-1H-inden-4-yl)oxy]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide (1, 
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(BI-4464), 83 mg, 75% yield) as off-white lyophilizate. 1H NMR (500 MHz, DMSO-d6) δ = 8.83 
(br s, 1H), 8.69 (s, 1H), 8.13 (d, J=7.57 Hz, 1H), 7.77 (dd, J=7.57, 7.88 Hz, 1H), 7.55 (d, J=7.57 
Hz, 1H), 7.38 (d, J=0.95 Hz, 1H), 7.22 (d, J=7.88 Hz, 1H), 7.27 (br s, 1H), 7.12 (br s, 1H), 3.78 
(s, 3H), 3.66-3.75 (m, 1H), 3.04-3.15 (m, 2H), 2.78 (br d, J=11.35 Hz, 2H), 2.16 (s, 3H), 1.85-
1.98 (m, 2H), 1.69-1.80 (m, 2H), 1.49-1.65 (m, 2H), two protons under DMSO. 13C NMR (125 
MHz, DMSO-d6) δ = 201.3, 164.2, 163.2, 159.1, 156.2, 155.7, 148.0, 145.8, 134.8, 128.8, 127.8, 
126.8, 123.3, 118.8, 121.9, 117.5, 108.1, 99.0, 54.2, 53.0, 45.0, 44.4, 34.6, 29.9, 23.7, one carbon 
not detected. HRMS (m/z): [M+H]+ calculated for C28H28F3N5O4, 555.20934; found, 555.20824. 
HPLC-MS tR = 1.39 min.
3-{2-[2-(2-azidoethoxy)ethoxy]ethoxy}-N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-
dihydro-1H-isoindol-4-yl]propanamide (5a). In a 50 mL round-bottom flask, 4-amino-2-(2,6-
dioxo-3-piperidyl)isoindoline-1,3-dione (500 mg, 1 eq) was dissolved in DMF (5 mL) and 
cooled to 0°C in an ice bath. 3-{2-[2-(2-azidoethoxy)ethoxy]ethoxy}propanoic acid (905 mg, 2 
eq) was added dropwise. Then N-propylphosphonic acid anhydride, cyclic trimer (7.0 g, 6.5 mL, 
6 eq) and pyridine (1.5 mL, 10 eq) were added. The mixture was stirred at 80°C for 3h. The 
reaction mixture was diluted with ACN/H2O. The solution was filtered through a syringe filter 
and purified by preparative RP-HPLC under basic conditions using MeCN/H2O as eluents in a 
gradient from 10:90 to 60:40 over 9 min. (column: XBridge™ Prep C18, OBD™ 10 µm, 50x150 
mm; flow: 150 mL/min). Product containing fractions were freeze dried to give 3-{2-[2-(2-
azidoethoxy)ethoxy]ethoxy}-N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-
4-yl]propanamide (5a, 697 mg, 76% yield) as yellow lyophylizate. 1H NMR (500 MHz, DMSO-
d6) δ = 11.15 (s, 1H), 9.88 (s, 1H), 8.54 (d, J=8.31 Hz, 1H), 7.83 (dd, J=7.26, 8.31 Hz, 1H), 7.62 
(d, J=7.26 Hz, 1H), 5.14 (dd, J=5.52, 12.77 Hz, 1H), 3.74 (t, J=5.83 Hz, 2H), 3.52-3.61 (m, 6H), 
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3.47-3.52 (m, 4H), 3.34-3.37 (m, 2H), 2.84-2.96 (m, 1H), 2.70 (t, J=5.99 Hz, 2H), 2.53-2.66 (m, 
2H), 2.00-2.12 (m, 1H). 13C NMR (125 MHz, DMSO-d6) δ = 173.2, 170.9, 170.2, 168.1, 167.1, 
136.9, 136.6, 131.9, 126.5, 118.7, 117.1, 70.2, 70.2, 70.1, 70.1, 69.7, 66.6, 50.4, 49.4, 38.0, 31.4, 
22.4. HRMS (m/z): [M+H]+ calculated for C22H26N6O8, 502.18121; found, 502.18114. HPLC-
MS tR = 1.05 min.
3-{2-[2-(2-aminoethoxy)ethoxy]ethoxy}-N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-
dihydro-1H-isoindol-4-yl]propanamide (5b). In a Parr-reactor 3-{2-[2-(2-
azidoethoxy)ethoxy]ethoxy}-N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-
4-yl]propanamide (5a, 190 mg, 1 eq) was dissolved in methanol (5 mL) and Pd/C (10%, 40 mg, 
0.1 eq) was added. The reactor was flushed with N2 and filled with H2 (6 bar). The reaction 
mixture was stirred at rt for 3 h. A spoon of celite was added to the reaction mixture, the catalyst 
was filtered off through a celite pad and rinsed with DCM and MeOH. The filtrate was 
concentrated under reduced pressure. 3-{2-[2-(2-aminoethoxy)ethoxy]ethoxy}-N-[2-(2,6-
dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]propanamide (5b, 162 mg, 90% 
yield) was obtained as yellow resin. The product was taken to the next step without further 
purification. 1H NMR (500 MHz, DMSO-d6) δ = ppm 9.89 (br s, 1 H), 8.54 (d, J=8.20 Hz, 1 H), 
8.36 (s, 1 H), 7.84 (dd, J=8.20, 7.25 Hz, 1 H), 7.62 (br d, J=7.25 Hz, 1 H), 5.14 (dd, J=12.93, 
5.36 Hz, 1 H), 3.71 - 3.77 (m, 2 H), 3.45 - 3.60 (m, overlapped), 2.85 - 2.96 (m, 2 H), 2.82 (br t, 
J=5.36 Hz, 2 H), 2.71 (br t, J=5.83 Hz, 2 H), 2.02 - 2.11 (m, 1 H). 13C NMR (125 MHz, DMSO-
d6) δ = 173.3, 170.9, 170.3, 168.1, 167.1, 136.9, 136.7, 131.9, 126.5, 118.8, 117.2, 70.2, 70.1, 
70.1, 70.0, 69.2, 66.6, 49.4, 39.8, 38.0, 31.4, 22.4. HRMS (m/z): [M+H]+ calculated for 
C22H28N4O8, 476.19071; found, 476.19041. HPLC-MS tR = 0.81 min.
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N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-3-{2-[2-(2-{[3-
methoxy-4-({4-[(3-oxo-2,3-dihydro-1H-inden-4-yl)oxy]-5-(trifluoromethyl)pyrimidin-2-
yl}amino)phenyl]formamido}ethoxy)ethoxy]ethoxy}propanamide (6, BI-3663). In a glass 
vial, 3-methoxy-4-({4-[(3-oxo-2,3-dihydro-1H-inden-4-yl)oxy]-5-(trifluoromethyl)pyrimidin-2-
yl}amino)benzoic acid (2, 170 mg, 1 eq) was dissolved in DMF (2 mL). DIPEA (150 µL, 3 eq) 
and HATU (155 mg, 1.2 eq) were added. The reaction mixture was stirred at rt for 5 min, then 3-
{2-[2-(2-aminoethoxy)ethoxy]ethoxy}-N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-
1H-isoindol-4-yl]propanamide (5b, 162 mg, 1eq) was added. The mixture was stirred at rt 
overnight. The reaction mixture was diluted with MeCN and H2O and filtered through a syringe 
filter prior to purification via RP-HPLC under acidic conditions using MeCN/H2O as eluents in a 
gradient from 30:70 to 98:2 over 8 min (column: YMC Actus-Triart Prep C18, 5 µm, 30x50 mm; 
flow: 50 mL/min). Product containing fractions were freeze dried to give N-[2-(2,6-
dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-3-{2-[2-(2-{[3-methoxy-4-({4-
[(3-oxo-2,3-dihydro-1H-inden-4-yl)oxy]-5-(trifluoromethyl)pyrimidin-2-
yl}amino)phenyl]formamido}ethoxy)ethoxy]ethoxy}propanamide (6 (BI-3663), 32 mg, 10% 
yield) as off-white lyophilizate. 1H NMR (500 MHz, DMSO-d6) δ = 11.13 (br s, 1H), 9.86 (s, 
1H), 8.79 (br s, 1H), 8.70 (s, 1H), 8.53 (d, J=8.51 Hz, 1H), 8.43 (t, J=5.52 Hz, 1H), 7.81 (dd, 
J=7.25, 8.51 Hz, 1H), 7.77 (t, J=7.88 Hz, 1H), 7.60 (d, J=7.25 Hz, 1H), 7.56 (d, J=7.88 Hz, 1H), 
7.40 (s, 1H), 7.21 (d, J=7.88 Hz, 1H), 7.25 (br s, 1H), 7.10 (br s, 1H), 5.14 (dd, J=5.52, 12.77 
Hz, 1H), 3.78 (s, 3H), 3.71 (t, J=5.99 Hz, 2H), 3.43-3.61 (m, 10H), 3.36-3.41 (m, 2H), 3.07-3.15 
(m, 2H), 2.84-2.95 (m, 1H), 2.68 (t, J=5.99 Hz, 2H), 2.52-2.65 (m, 2H), 2.02-2.11 (m, 1H), two 
protons under DMSO. 13C NMR (125 MHz, DMSO-d6) δ = 203.4, 173.2, 170.9, 170.3, 168.1, 
167.1, 166.4, 165.9, 161.1, 158.3, 157.8, 149.9, 147.9, 136.9, 136.9, 136.6, 131.9, 130.4, 130.0, 
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128.9, 126.4, 125.5, 120.9, 124.0, 119.5, 118.7, 117.1, 110.2, 101.2, 70.2, 70.2, 70.1, 70.0, 69.5, 
66.6, 56.3, 49.4, 39.6, 38.0, 36.8, 31.4, 25.8, 22.4, one carbon not detected. HRMS (m/z): 
[M+H]+ calculated for C44H42F3N7O12, 917.28435; found, 917.28471. HPLC-MS tR = 1.35 min.
(2S,4R)-1-[(2S)-2-(2-{2-[2-(2-azidoethoxy)ethoxy]ethoxy}acetamido)-3,3-dimethyl- 
butanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-
carboxamide (7a).  (2S,4R)-1-[(2S)-2-amino-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-
methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide hydrochloride (2, 1.000 g, 1 eq) 
was dissolved in DMF (5 mL). HATU (855 mg, 1.05 eq) and DIPEA (1.28 mL, 3.5 eq) were 
added. The reaction mixture was stirred for 15 min, then 2-[2-[2-(2-
azidoethoxy)ethoxy]ethoxy]acetic acid (524 mg, 1.05 eq) was added. The reaction mixture was 
stirred at rt for 1 h. The reaction mixture was diluted with EtOAc and washed with a saturated 
solution of NaHCO3 and then with brine. The organic layer is dried over MgSO4 and evaporated. 
The residue was purified via RP-HPLC under acidic conditions using MeCN/H2O as eluents in a 
gradient from 10:90 to 98:2 over 10 min (column: Sunfire™ Prep C18, OBD™ 10 µm, 50x150 
mm; flow: 120 mL/min). Product containing fractions were freeze dried to give (2S,4R)-1-[(2S)-
2-(2-{2-[2-(2-azidoethoxy)ethoxy]ethoxy}acetamido)-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-
(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (7a, 870 mg, 63% yield). 
1H NMR (500 MHz, DMSO-d6) δ = 8.98 (s, 1H), 8.60 (t, J=5.99 Hz, 1H), 7.35-7.47 (m, 5H), 
4.67-5.61 (m, 1H), 4.57 (d, J=9.77 Hz, 1H), 4.32-4.48 (m, 3H), 4.21-4.29 (m, 1H), 3.97 (s, 2H), 
3.64-3.69 (m, 1H), 3.53-3.64 (m, 12H), 2.44 (s, 3H), 2.02-2.09 (m, 1H), 1.85-1.94 (m, 1H), 0.93-
0.96 (m, 8H), 0.94 (s, 1H), one proton under water. 13C NMR (125 MHz, DMSO-d6) δ = 172.2, 
169.6, 169.1, 152.0, 148.2, 139.9, 131.6, 130.2, 129.2, 127.9, 70.9, 70.4, 70.2, 70.1, 70.1, 69.7, 
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69.3, 59.2, 57.0, 56.1, 50.4, 42.1, 38.4, 36.2, 26.6, 16.4. HRMS (m/z): [M+H]+ calculated for 
C30H43N7O7S, 645.29447; found, 645.29442. HPLC-MS tR = 1.16 min.
(2S,4R)-1-[(2S)-2-(2-{2-[2-(2-aminoethoxy)ethoxy]ethoxy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-
2-carboxamide (7b). (2S,4R)-1-[(2S)-2-(2-{2-[2-(2-azidoethoxy)ethoxy]ethoxy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-
carboxamide (7a, 1.475 g, 1 eq) was dissolved in MeOH (10 mL), Pd/C (250 mg, 10 %) was 
added and the mixture was hydrogenated (5 bar H2 pressure) at rt for 2.5 h. The catalyst was 
filtered off and the filtrate was purified via RP-HPLC under basic conditions using MeCN/H2O 
as eluents in a gradient from 10:90 to 90:10 over 10 min. (column: XBridge™ Prep C18, OBD™ 
10 µm, 50x150 mm; flow: 140 mL/min). Product containing fractions were freeze dried to give 
(2S,4R)-1-[(2S)-2-(2-{2-[2-(2-aminoethoxy)ethoxy]ethoxy}acetamido)-3,3-dimethylbutanoyl]-4-
hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (7b, 1.166 
g, 82% yield). 1H NMR (500 MHz, DMSO-d6) δ = 9.00 (s, 1H), 8.64 (t, J=6.00 Hz, 1H), 7.37-
7.49 (m, 5H), 5.17 (br s, 1H), 4.58 (br d, J=9.46 Hz, 1H), 4.21-4.48 (m, 4H), 3.99 (s, 2H), 3.65-
3.71 (m, 1H), 3.51-3.65 (m, 9H), 3.46 (t, J=5.50 Hz, 1H), 2.79 (t, J=5.67 Hz, 1H), 2.45 (s, 3H), 
2.02-2.11 (m, 1H), 1.86-1.96 (m, 1H), 0.95 (s, 9H), two protons not detected (NH2). 13C NMR 
(125 MHz, DMSO-d6) δ = 172.2, 169.6, 169.1, 152.0, 148.2, 139.9, 131.6, 130.2, 129.2, 127.9, 
70.9, 70.4, 70.2, 70.1, 70.1, 70.0, 69.3, 59.2, 57.1, 56.2, 42.1, 38.4, 36.2, 26.7, 16.4, one carbon 
not detected. HRMS (m/z): [M+H]+ calculated for C30H45N5O7S, 619.30397; found, 619.30333. 
HPLC-MS tR = 1.00 min.
(2S,4R)-4-hydroxy-1-[(2S)-2-(2-{2-[2-(2-{[3-methoxy-4-({4-[(3-oxo-2,3-dihydro-1H-inden-
4-yl)oxy]-5-(trifluoromethyl)pyrimidin-2-yl}amino)phenyl]formamido}ethoxy) 
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ethoxy]ethoxy}acetamido)-3,3-dimethylbutanoyl]-N-{[4-(4-methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide (8, BI-0319). In a 50 mL round-bottom flask, 3-
methoxy-4-({4-[(3-oxo-2,3-dihydro-1H-inden-4-yl)oxy]-5-(trifluoromethyl)pyrimidin-2-
yl}amino)benzoic acid (2, 111 mg, 1 eq)was dissolved in DMF (3 mL). DIPEA (96 µl, 3 eq) and 
HATU (101 mg; 266 µmol; 1.2 eq) were added. The reaction mixture was stirred at rt for 5 min, 
then (2S,4R)-1-[(2S)-2-[[2-[2-[2-(2-aminoethoxy)ethoxy] ethoxy]acetyl]amino]-3,3-dimethyl-
butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (7b, 
150 mg, 1 eq) was added. The mixture was stirred at rt for 24h. The reaction mixture was diluted 
with MeCN and H2O and filtered through a syringe filter prior to purification via RP-HPLC 
under basic conditions using MeCN/H2O as eluents in a gradient from 25:75 to 90:10 over 9 
min. (column: XBridge™ Prep C18, OBD™ 10 µm, 50x150 mm; flow: 150 mL/min). The 
product containing fractions were pooled and freeze-dried to give (2S,4R)-4-hydroxy-1-[(2S)-2-
(2-{2-[2-(2-{[3-methoxy-4-({4-[(3-oxo-2,3-dihydro-1H-inden-4-yl)oxy]-5-
(trifluoromethyl)pyrimidin-2-yl}amino)phenyl]formamido}ethoxy)ethoxy]ethoxy}acetamido)-
3,3-dimethylbutanoyl]-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-
carboxamide (8 (BI-0319), 81 mg, 34% yield) as colorless lyophilizate. 1H NMR (500 MHz, 
DMSO-d6) δ = 8.97 (s, 1H), 8.80 (br s, 1H), 8.70 (s, 1H), 8.59 (t, J=5.99 Hz, 1H), 8.46 (t, J=5.67 
Hz, 1H), 7.77 (dd, J=7.57, 7.88 Hz, 1H), 7.56 (d, J=7.57 Hz, 1H), 7.35-7.46 (m, 6H), 7.21 (d, 
J=7.88 Hz, 1H), 7.23 (br s, 1H), 7.11 (br s, 1H), 5.15 (d, J=3.47 Hz, 1H), 4.56 (d, J=9.77 Hz, 
1H), 4.20-4.48 (m, 4H), 3.96 (s, 2H), 3.77 (s, 3H), 3.36-3.71 (m, 16H), 3.06-3.15 (m, 2H), 2.43 
(s, 3H), 2.00-2.10 (m, 1H), 1.85-1.94 (m, 1H), 0.93 (s, 9H). 13C NMR (125 MHz, DMSO-d6) δ = 
203.4, 172.2, 169.6, 169.1, 166.4, 166.0, 161.1, 158.3, 157.8, 151.9, 150.0, 148.2, 147.9, 139.9, 
136.9, 131.6, 130.4, 130.2, 130.0, 129.1, 128.9, 127.9, 125.5, 121.0, 124.0, 119.5, 110.2, 101.3, 
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101.1, 70.9, 70.3, 70.2, 70.1, 70.0, 69.5, 69.3, 59.2, 57.0, 56.3, 56.2, 42.1, 38.4, 36.8, 36.2, 26.6, 
25.8, 16.4. HRMS (m/z): [M+H]+ calculated for C52H59F3N8O11S, 1060.39761; found, 
1060.39604. HPLC-MS tR = 1.35 min.
(2S,4S)-1-[(2S)-2-(2-{2-[2-(2-azidoethoxy)ethoxy]ethoxy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-
2-carboxamide (10a). In a glass vial 2-[2-[2-(2-azidoethoxy) ethoxy] ethoxy]acetic acid (9, 569 
mg, 1.05 eq) was dissolved in DMF (1 mL) and DIPEA (768 µl, 2 eq). HATU (1.324 g 1.5 eq) 
and (2S,4S)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide (1.000 g, 1 eq) were added. The mixture was 
stirred at rt for 2 h. The reaction mixture was diluted with EtOAc and washed with a saturated 
solution of NaHCO3 then with brine. The organic layer was evaporated and the residue was 
dissolved in MeOH and purified via RP-HPLC under acidic conditions using MeCN/H2O as 
eluents in a gradient from 15:85 to 98:2 over 10 min (column: Sunfire™ Prep C18, OBD™ 10 
µm, 50x150 mm; flow: 120 mL/min). Product containing fractions were freeze dried to give 
(2S,4S)-1-[(2S)-2-(2-{2-[2-(2-azidoethoxy)ethoxy]ethoxy}acetamido)-3,3-dimethylbutanoyl]-4-
hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (10a, 700 
mg, 47% yield). 1H NMR (500 MHz, DMSO-d6) δ = 8.99 (s, 1H), 8.67 (t, J=5.99 Hz, 1H), 7.36-
7.43 (m, 5H), 5.36 (br s, 1H), 4.52 (d, J=9.14 Hz, 1H), 4.18-4.47 (m, 4H), 3.95 (s, 2H), 3.84-3.91 
(m, 1H), 3.51-3.64 (m, 11H), 3.43-3.48 (m, 1H), 2.44 (s, 3H), 2.29-2.39 (m, 1H), 1.68-1.79 (m, 
1H), 0.96 (s, 9H), one proton under water. 13C NMR (125 MHz, DMSO-d6) δ = 172.7, 169.8, 
169.3, 152.0, 148.2, 139.6, 131.6, 130.2, 129.2, 127.9, 70.9, 70.3, 70.2, 70.1, 70.0, 69.7, 69.5, 
59.0, 56.3, 56.1, 50.4, 42.3, 37.4, 35.6, 26.6, 16.4. HRMS (m/z): [M+H]+ calculated for 
C30H43N7O7S, 645.29447; found, 645.29368. HPLC-MS tR = 1.18 min.
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(2S,4S)-1-[(2S)-2-(2-{2-[2-(2-aminoethoxy)ethoxy]ethoxy}acetamido)-3,3-dimethyl 
butanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-
carboxamide (10b). In a Parr-reactor (2S,4S)-1-[(2S)-2-(2-{2-[2-(2-
azidoethoxy)ethoxy]ethoxy}acetamido)-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-
thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (10a, 153 mg, 1 eq) was dissolved in 
methanol (5 mL) and Pd/C (10%, 25 mg, 0.1 eq) was added. The reactor was flushed with N2 and 
filled with H2 (6 bar). The reaction mixture was allowed to at rt for 3 h. A spoon of celite was 
added to the reaction mixture, the catalyst was filtered off through a pad of celite and rinsed with 
DCM and MeOH. The filtrate was concentrated under reduced pressure. (2S,4S)-1-[(2S)-2-(2-{2-
[2-(2-aminoethoxy)ethoxy]ethoxy}acetamido)-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (10b, 144 mg, 98% yield) 
was obtained as colorless resin. The product was taken to the next step without further 
purification. 1H NMR (500 MHz, DMSO-d6) δ = 8.99 (s, 1H), 8.72 (br t, J=5.83 Hz, 1H), 8.36 
(br s, 1H), 7.40 (s, 4H), 5.32 (br s, 1H), 4.52 (d, J=9.14 Hz, 1H), 4.18-4.45 (m, 4H), 3.96 (s, 2H), 
3.86-3.91 (m, 1H), 3.42-3.62 (m, 11H), 2.82 (br s, 2H), 2.44 (s, 3H), 2.31-2.38 (m, 1H), 1.68-
1.79 (m, 1H), 0.96 (s, 9H), two protons not detected (NH2). 13C NMR (125 MHz, DMSO-d6) δ = 
172.7, 169.8, 169.4, 152.0, 148.2, 139.7, 131.6, 130.2, 129.2, 127.9, 70.8, 70.2, 70.1, 70.1, 70.0, 
69.5, 59.0, 56.3, 56.1, 42.3, 37.4, 35.7, 26.6, 16.4, two carbons not detected. HRMS (m/z): 
[M+H]+ calculated for C30H45N5O7S, 619.30397; found, 619.30308. HPLC-MS tR = 1.01 min.
(2S,4S)-4-hydroxy-1-[(2S)-2-(2-{2-[2-(2-{[3-methoxy-4-({4-[(3-oxo-2,3-dihydro-1H-inden-
4-yl)oxy]-5-(trifluoromethyl)pyrimidin-2-yl}amino)phenyl]formamido}ethoxy) 
ethoxy]ethoxy}acetamido)-3,3-dimethylbutanoyl]-N-{[4-(4-methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide (11, BI-4206). In a glass vial, 3-methoxy-4-({4-
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[(3-oxo-2,3-dihydro-1H-inden-4-yl)oxy]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzoic acid 
(2, 116 mg, 1 eq) was dissolved in DMF (2 mL). DIPEA (100 µL, 3 eq) and HATU (106 mg, 1.2 
eq) were added. The reaction mixture was stirred at rt for 5 min, then (2S,4S)-1-[(2S)-2-(2-{2-[2-
(2-aminoethoxy)ethoxy]ethoxy}acetamido)-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-
1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (10b, 144 mg, 1 eq) was added. The 
mixture was stirred at rt for 16 h. The reaction mixture was diluted with MeCN and H2O and 
filtered through a syringe filter prior to purification via RP-HPLC under basic conditions using 
MeCN/H2O as eluents in a gradient from 30:70 to 98:2 over 8 min (column: YMC Actus-Triart 
Prep C18, 5 µm, 30x50 mm; flow: 50 mL/min). Product containing fractions were freeze dried to 
give (2S,4S)-4-hydroxy-1-[(2S)-2-(2-{2-[2-(2-{[3-methoxy-4-({4-[(3-oxo-2,3-dihydro-1H-inden-
4-yl)oxy]-5-(trifluoromethyl)pyrimidin-2-yl}amino)phenyl]formamido}ethoxy) 
ethoxy]ethoxy}acetamido)-3,3-dimethylbutanoyl]-N-{[4-(4-methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide (11, (BI-4206), 169 mg, 69% yield) as off-white 
lyophilizate. 1H NMR (500 MHz, DMSO-d6) δ = 8.97 (s, 1H), 8.81 (br s, 1H), 8.70 (s, 1H), 8.66 
(t, J=5.99 Hz, 1H), 8.45 (t, J=5.52 Hz, 1H), 7.77 (dd, J=7.57, 7.88 Hz, 1H), 7.56 (d, J=7.57 Hz, 
1H), 7.35-7.45 (m, 6H), 7.21 (d, J=7.88 Hz, 1H), 7.25 (br s, 1H), 7.11 (br s, 1H), 5.45 (br d, 
J=6.62 Hz, 1H), 4.51 (d, J=9.14 Hz, 1H), 4.17-4.45 (m, 4H), 3.94 (s, 2H), 3.84-3.91 (m, 1H), 
3.77 (s, 3H), 3.36-3.62 (m, 15H), 3.07-3.15 (m, 2H), 2.43 (s, 3H), 2.29-2.36 (m, 1H), 1.69-1.79 
(m, 1H), 0.95 (s, 9H). 13C NMR (125 MHz, DMSO-d6) δ = 203.4, 172.7, 169.8, 169.4, 166.4, 
166.0, 161.1, 158.3, 157.8, 151.9, 150.0, 148.2, 147.9, 139.6, 136.9, 131.6, 130.4, 130.2, 130.0, 
129.2, 128.9, 127.9, 125.5, 121.0, 124.0, 119.5, 110.2, 101.3, 101.1, 70.9, 70.2, 70.1, 70.1, 70.0, 
69.5, 69.5, 59.0, 56.3, 56.1, 42.3, 37.4, 36.8, 35.6, 26.6, 25.8, 16.4, two carbons not detected. 
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HRMS (m/z): [M+H]+ calculated for C52H59F3N8O11S, 1060.39761; found, 1060.39665. HPLC-
MS tR = 1.71 min.
Protein expression and purification. 
Human PTK2 (residues 411–689, UniProt accession number Q05397) with an N-terminal TEV 
cleavage site was cloned into pDEST20 vector (Invitrogen). Expression in this vector results in a 
fusion protein with a cleavable GST tag. Viral stocks were generated in the Bac-to-Bac system 
(Invitrogen) and used to infect Trichoplusia ni (Hi5) cells (Invitrogen). Recombinant protein was 
isolated from cell extracts by affinity chromatography over glutathione sepharose (GE 
Healthcare) in batch mode. The GST-tag was removed by incubation with Ac-TEV protease 
(ThermoFisher) on the resin, overnight at 4 °C. Cleaved protein was recovered, concentrated 
(biomax 10, Merck) and finally purified by size exclusion chromatography on HiLoad Superdex 
S75 (GE Healthcare). The protein was concentrated (biomax 10, Merck) to 5 mg/ml and stored 
in 20 mM HEPES, 250 mM NaCl, 1 mM DTT, 1 mM EDTA, pH 6.7 at -80 °C.
Crystallization of the PTK2 kinasedomain BI 4464 binary complex. 
Protein crystallization was done using the sitting drop method by incubating the protein with 
1 mM BI 4464 (as 50 mM stock solution) and mixing 0.2 µL of PTK2 (4.5 mg/mL in 25 mM 
HEPES pH 6.7, 250 mM NaCl, 1 mM DTT, 1 mM EDTA) with 0.2 µL of reservoir solution 
(7 % PEG 1500, 100 mM SPG buffer pH 6.0) at 4 °C. Crystals grew as thin plates within a few 
days to a final size of 150-200 µm). Crystals were transferred to a cryo buffer (reservoir solution 
with 15 % ethylene glycol) and frozen in liquid nitrogen. Data were collected at the SLS beam 
line X06DA (Swiss Light Source, Paul Scherrer Institute) at a wavelength of 0.91 Å using the 
PILATUS 2M detector. The crystals belonged to space group P21212 with 1 monomer per 
asymmetric unit. Images were processed with XDS48. The structures were solved by molecular 
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replacement using the PDB: 2ETM as a search model. Subsequent model building and 
refinement was done using standard protocols using CCP449 , COOT50 and autoBUSTER51. Unit 
cell parameters were a = 48.05 Å, b = 77.09 Å, c = 82.71 Å and α, β, γ = 90° data and the 
structure was refined to R and Rfree values of 18.3 % and 22.2 %, respectively, with 98.1 % of the 
residues in Ramachandran favored regions as validated with Molprobity52. Statistics for data 
collection and refinement can be found in supplemental table 2. The coordinates and structure 
factors of the structures have been deposited at the Protein Data Bank with the accession code 
6I8Z. The authors will release the atomic coordinates and experimental data upon article 
publication
Cell culture. 
Cell lines were obtained through ATCC or JCRB, verified for identity by satellite repeat 
analysis, tested for mycoplasm contamination at regular intervals and cultured in the specified 
media in a humidified cell incubator at 37 °C and 5 % CO2. DMEM was obtained from Lonza 
(product code BE12-604F), EMEM from ATCC (product code 30-2003),IMDM from Thermo 
Fisher (product code 12440053), RPMI-1640 from Thermo Fisher (product code A1049101). 
The following cell lines (product codes and culture media in parentheses) were used for the 
described experiments: SNU-387 (CRL-2237, RPMI-1640 plus 10 % heat inactivated FCS), 
HUH-1 (JCRB0199, DMEM plus 10 % FCS), Hep3B2.1-7 (HB-8064, EMEM plus 10 % FCS), 
HepG2 (HB-8065, EMEM plus 10 % FCS plus Glutamax), SK-Hep-1 HLF (JCRB0404 DMEM 
plus 10 % FCS), SNU-398 (CRL-2233, RPMI1640 plus 10 % FCS), HUCCT1 (JCRB0425, 
RPMI-1640 plus 10 % FCS), HLE (JCRB0405, DMEM plus 10 % FCS), HuH-7 (JCRB0403 
DMEM plus 10 % FCS), SNU-423 (CRL-2238, RPMI-1640 plus 10 % FCS), A549 (CCL-185, 
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F-12K plus 10 % heat inactivated FCS), HSC-3 (JCRB0623, EMEM plus 10 % FCS), C32 
(CRL-1585, EMEM plus 10 % FCS), CFPAC-1 (CRL-1918, IMDM plus 10 % FCS).
Protein degradation assays. 
To quantify the effects of compounds on PTK2 protein levels, cells were seeded at a density of 
125.000 cells in 0.75 mL of culture medium 24-well plates and allowed to attach for 6-8 hours. 
Subsequently, compounds were added to the cells at logarithmic dose series using the HP Digital 
Dispenser D300 (Tecan), normalizing for added DMSO. After compound addition, cells were 
incubated for 18 h or the specified time intervals at 37 °C. Cells were washed with cold PBS and 
lysed by immediate freezing in 100 µL RIPA buffer (Sigma product code R0278) supplemented 
with 1:100 HALT Phosphatase-Protease Inhibitors (Thermo product code 1861281) at -80 °C. 
After thawing, samples were transferred into V-bottom 96-well plates, cellular debris was 
sedimented at 4000 rpm (Eppendorf centrifuge 5810R, rotor A-4-81). 90 µL of the supernatant 
were transferred into a new 96-well plate and analyzed using a Wes capillary electrophoresis 
instrument (Proteinsimple) using PTK2 antibody (Cell Signaling product code 13009) at a 
dilution of 1:50 or PDE6D antibody (Abcam product code ab5665) at a dilution of 1:25 and 
GAPDH antibody (Abcam product code ab9485) at a dilution of 1:2000 for normalization.
Proliferation assays. 
Standard proliferation assay. To test the effect of PTK2 PROTACs on proliferation, cells were 
seeded at 1000 cells per well (2500 cells per well for suspension cell lines) in 100 µL growth 
medium in a white bottom opaque 96-well plate and allowed to grow over night. To obtain 
starting densities, a set of cells seeded in parallel were lysed and measured using 100 µL 
CellTiter-Glo luminescent cell viability reagent (Promega product code G7570) per well as per 
manufacturer’s recommendation. Compounds were added to the cells at logarithmic dose series 
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using the HP Digital Dispenser D300 (Tecan), normalizing for added DMSO. Doxorubicin 
(Sigma product code D1515) was used as a positive control. Upon compound addition, cells 
were incubated for six days and viability measured CellTiterGlow reagent as described above. 
Results are stated as mean and standard deviation of triplicate experiments.
Anchorage independent growth assays. Cells were seeded in 0.3 % agarose (Gibco product 
code 18300-012) containing cultivation medium (60 µL) on top of a bottom layer composed of 
1.2 % agarose in cultivation medium (90 µL) in 96-well plates. Upon solidification of the cell 
layer, the culture was overlaid with 50 µL cultivation medium and compounds were added as 
indicated above. Cultures were allowed to grow for 7-14 days, stained with alamar blue reagent 
(Thermo Fisher product code DAL1025) and measured using a fluorescence plate reader (Wallac 
Victor 1420, 544 nm excitation, 590 nm emission, 0.2 s).   
Long-term proliferation assay. Cells were inoculated at a density of 250,000 cells in 1.5 mL 
culture medium in 6 well plates. Compounds or DMSO were added, and every 3 to 4 days cells 
were split to 250,000 cells. Upon splitting, fresh compound was added to keep the concentration 
constant. Split rates were recorded and multiplied to derive cumulative cell counts which were 
converted into population doublings (n) using the formula n = (log(Nx) – log(N0)) / log2 with Nx 
indicating the cumulative cell count at time-point x and N0 the initial seeding cell count.
MS proteomics. 
Sample preparation. A549 cells were seeded at 5 × 106 cells/mL in a 10 cm plate 18 h before 
treatment. Cells were treated with 0.1% DMSO as vehicle control, 3 µM of either active 
PROTAC 6 or 8, and 3 µM of cisVHL 11 as negative control. Cells were incubated at 37 °C and 
5 % CO2 for 18 h before harvesting. Cells were washed twice with DPBS (Gibco) and lysed with 
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0.5 mL of 100 mM Tris pH 8.0, 4 % (w/v) SDS, supplemented with cOmplete™ Mini EDTA-
free Protease Inhibitor Cocktail (Roche). Lysates were sonicated (2 x 10 s) and centrifuged at 
14,000 rpm for 20 min at 4 ˚C. The supernatant fraction of the cell extract was collected and 
protein concentration was quantified by BCA assay (Thermo Fisher Scientific). Further sample 
processing, digestion, desalting, TMT 10-plex isobaric labelling were performed as previously 
described.5 After labelling, the peptides from the 9 samples were pooled together in equal 
proportion. The pooled sample was fractionated using high pH reverse-phase chromatography on 
an XBridge peptide BEH column (130 Å, 3.5 μm, 2.1 × 150 mm, Waters) on an Ultimate 3000 
HPLC system (Thermo Scientific/Dionex). A mixture of Buffer A (10 mM ammonium formate 
in water, pH 9) and B (10 mM ammonium formate in 90 % CH3CN, pH 9) was used over a 
linear gradient of 5 % to 60 % buffer B over 60 min at a flow rate of 200 μL/min. The peptides 
eluted from the column were collected in 80 fractions before concatenation into 20 fractions 
based on the UV signal of each fraction. All the fractions were dried in a Genevac EZ-2 
concentrator and resuspended in 1 % formic acid for MS analysis.
nLC-MS/MS analysis. The fractions were analyzed sequentially on a Q Exactive HF-X Hybrid 
Quadrupole-Orbitrap Mass Spectrometer (Thermo Scientific) coupled to an UltiMate 3000 
RSLCnano UHPLC system (Thermo Scientific) and EasySpray column (75 μm × 50 cm, 
PepMap RSLC C18 column, 2 μm, 100 Å, Thermo Scientific). A mix of buffer A (0.1 % formic 
acid in H2O) and B (0.08 % formic acid in 80 % CH3CN) was used over a linear gradient from 
5 % to 35 % buffer B over 125 min using a flow rate of 300 nL/min. The column temperature 
was set at 50 °C. The mass Spectrometer was operated in data dependent mode with a single MS 
survey scan from 335-1,600 m/z followed by 15 sequential m/z dependent MS2 scans. The 15 
most intense precursor ions were sequentially fragmented by higher energy collision dissociation 
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(HCD). The MS1 isolation window was set to 0.7 m/z and the resolution set at 120,000. MS2 
resolution was set at 45,000. The AGC targets for MS1 and MS2 were set at 3e6 ions and 1e5 
ions, respectively. The normalized collision energy was set at 32 %. The maximum ion injection 
times for MS1 and MS2 were set at 50 ms and 200 ms, respectively.
Peptide and protein identification and quantification. The raw MS data files for all 20 fractions 
were merged and searched against the Uniprot-sprot-Human-Canonical database by Maxquant 
software 1.6.0.16 for protein identification and TMT reporter ion quantitation. The 
identifications were based on the following criteria: enzyme used Trypsin/P; maximum number 
of missed cleavages equal to two; precursor mass tolerance equal to 10 p.p.m.; fragment mass 
tolerance equal to 20 p.p.m.; variable modifications: Oxidation (M), Acetyl (N-term), 
Deamidation (NQ), Gln -> pyro-Glu (Q N-term); fixed modifications: Carbamidomethyl (C). 
The data was filtered by applying a 1 % false discovery rate followed by exclusion of proteins 
with less than two unique peptides. Quantified proteins were filtered if the absolute fold-change 
difference between the three DMSO replicates was ≥ 1.5.
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ABBREVIATIONS
NH4OAc, ammonium acetate; BET, bromodomain and extra-terminal; BRD2/3/4/7/9, 
bromodomain-containing protein 2/3/4/7/9; CRBN, cereblon; DLBCL, Diffuse Large B Cell 
Lymphoma; HCl, Hydrochloric acid; DIPEA, N,N-Diisopropylethylamine; EtOH, ethanol; 
EtOAc, ethyl acetate; H2O, water; HATU, 1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate; HOAt, 1-Hydroxy-7-azabenzotriazole 
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solution; MgSO4, magnesium sulfate; MsCl, methanesolfunyl chloride; PROTAC, proteolysis-
targeting chimera; NaHCO3, sodium bicarbonate; NaHDMS, Sodium bis(trimethylsilyl)amide; 
NaH, sodium hydride; NaOH, sodium hydroxide; NaIO4, sodium periodate; NaBH(OAc)3, 
sodium triacetoxyborohydride; OsO4, osmium tetroxide; TEMPO, 2,2,6,6-Tetramethyl-1-
piperidinyloxy; VHL; von Hippel-Lindau.
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Atomic coordinates and structure factors for PTK2:BI-4464 have been deposited to the Protein 
Data Bank (PDB) under accession number 6I8Z. Authors will release the atomic coordinates and 
experimental data upon article publication 
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